In brief
| What it is | The first GLP-1 agonist in tablet form |
| Weight loss | −11.2% over 72 weeks at the top dose |
| The injections | 15–20% over 12–18 months |
| Dosing | One tablet daily, with or without food |
| Where | United States yes, European Union no |
| On the label | A boxed warning for thyroid C-cell tumours |
The headline about orforglipron is almost always «the first weight-loss pill». True, but it shifts the emphasis: what is interesting here is not the drug's strength but that it exists as a tablet at all.
So, in order — what the trial showed, how that compares with the injections, and what the label says in small print.
Why the earlier drugs were injections only
Every drug of this class — semaglutide, liraglutide, tirzepatide — is a peptide, a small protein. And the stomach does precisely one thing to proteins: it breaks them down. To a stomach they are food, not medicine.
So the molecule has to be delivered past the digestion, hence the pen. Not because it works better that way, but because otherwise nothing arrives.
Orforglipron is built on a different principle: a non-peptide small molecule acting on the same receptor. It survives the stomach and is absorbed. Hence the tablet — not as a convenient version of the injection, but as a consequence of different chemistry.
One practical difference deserves naming: the label says the tablet is taken with or without food, once a day. The earlier oral drug of this class — semaglutide in tablets — has a stricter regimen: fasting, with a small amount of water, and a wait before breakfast.
What the trial showed
The main study is ATTAIN-1, published in the New England Journal of Medicine (PMID 40960239[1]). Phase 3, 3127 adults with obesity without diabetes, 72 weeks, three doses against placebo. Funded by Eli Lilly, the manufacturer.
| Group | Weight change at 72 weeks | 95% CI |
|---|---|---|
| Low dose | −7.5% | −8.2…−6.8 |
| Middle dose | −8.4% | −9.1…−7.7 |
| High dose | −11.2% | −12.0…−10.4 |
| Placebo | −2.1% | −2.8…−1.4 |
The mean, as usual, says less than the spread. At the top dose 54.6% of participants lost 10% or more of their weight, 36% lost 15% or more, and 18.4% lost 20% or more. On placebo the same marks were reached by 12.9%, 5.9% and 2.8%.
Other measures improved too: waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol.
How that compares with the injections
There are no head-to-head trials of the pill against the injections, so separate studies have to be set side by side — with the caveat that such a comparison is approximate.
A 2026 review (PMID 42701351[2]) puts semaglutide and tirzepatide at 15–20% weight loss over 12–18 months. Against 11.2% for the tablet over 72 weeks.
So what is it for? Because the injection is a barrier. Some people never start because of the needle, some stop within a month, some cannot manage cold storage. For them the choice is not between a pill and an injection but between a pill and nothing. Eleven per cent in someone who started beats nothing in someone who did not.
The dose confusion, and it is easy to fall into
Anyone who reads the trial and then looks at the box will think they have been given half.
The paper gives doses of 6, 12 and 36 mg. The box tops out at 17.2 mg, and the schedule starts at 0.8 mg, stepping up no more often than every thirty days.
There is no contradiction, and the explanation is in the label itself: effectiveness was established with an investigational formulation, and the data are presented «shown as equivalent dosages» of the marketed one.
The label prints no conversion table, but the groups line up unambiguously: its account has the same 3127 patients, the same 3:3:3:4 ratio and the same numbers per arm — 723, 725, 730 against 949 on placebo — with the doses named 5.5, 9 and 17.2 mg. The same people, described in two systems of measurement.
The practical conclusion is simple: a dose from the paper cannot be carried across to the box. The trial's top dose is the box's top dose under another name.
What it costs
The common adverse events are gastrointestinal, mostly mild to moderate. That is expected: nausea and altered stool accompany the whole class.
The cost in numbers: adverse events ended treatment for 5.3 to 10.3% of patients on the drug against 2.7% on placebo. Roughly one in ten at the top dose could not continue.
A curious detail from the label: overall, 22–24% left the trial in the drug groups and 30% on placebo. People abandoned the placebo more often — presumably because it did nothing.
What the label says first
The drug carries a boxed warning for thyroid C-cell tumours. It is worth reading whole, though, because the second sentence changes the first.
The box says this. In products with GLP-1 receptor activity that are pharmacologically active in rats and mice, such rodent tumours have been observed. Then, verbatim: «orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents». And third: while it is active at the human receptor, the human relevance of those rodent tumours has not been determined.
So the experiment that gave the whole class its warning does not technically apply to this molecule — it simply does not switch on the rodent receptor. The warning stands nonetheless, and the contraindications in it are real.
The contraindications are absolute and not open to discussion: medullary thyroid carcinoma in the patient or the family, and multiple endocrine neoplasia syndrome type 2. The label separately requires that patients be counselled on the symptoms of a thyroid tumour.
And one more: taking it alongside another drug of the class is not recommended. A tablet and an injection cannot be stacked for a double effect.
Who it is for
The indication reads: to reduce excess body weight and maintain the reduction long term in adults with obesity, or with overweight and at least one weight-related condition — and only in combination with a reduced-calorie diet and increased physical activity.
That frame matters. The drug is registered as treatment for a disease, not as a way to improve a figure, and the diet and activity in the indication are not a suggestion but part of the condition.
Where it exists
In the United States it is approved: the label was published in August 2026 and the drug is on sale.
The bottom line
Orforglipron does not overtake the injections and does not try to. It does something else — it removes the injection, and with it the fridge, the needle, and the barrier that stops some people from starting treatment at all.
It is not a slimming aid and not a harmless supplement: a prescription drug with a boxed warning, a titration running for months, and a clear share of people who could not tolerate it.
And the thing worth taking away: what is new here is the form, not the strength. Reading it as «new, therefore better» is a mistake of reading, not a property of the drug.
This article is for information. The drug is prescription-only; the decision to use it, the dose and the assessment of contraindications belong to a physician.
References
Key facts
- 11.2% weight loss over 72 weeks at the top dose against 2.1% on placebo (ATTAIN-1, 3127 adults with obesity without diabetes).
- The injections — semaglutide and tirzepatide — give 15–20% over 12–18 months. The pill is weaker, and that is not hidden.
- The point is the form, not the strength: the earlier drugs of the class are proteins, destroyed in the stomach, hence the needle. Orforglipron is a non-peptide small molecule.
- At the top dose 54.6% of participants lost 10% or more, 36% lost 15% or more, and 18.4% lost 20% or more.
- Adverse events ended treatment for 5.3 to 10.3% of patients against 2.7% on placebo.
- The label carries a boxed warning for thyroid C-cell tumours. It is a class effect of GLP-1 agonists, not a peculiarity of this drug.
- Approved and sold in the United States. Not authorised in the European Union and absent from national registers.
